Deciphera's TKI drug flops key test in earlier-line GI tumors, sending stock into a tailspin
Despite a very late line approval for its TKI drug last year, Deciphera has had its eyes set on cracking into earlier patients with GI …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
